Skip to content

Tandem Diabetes Care TNDM Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

Mannkind logo
MannkindMNKD
$81.03M-39.6%
Medtronic logo
MedtronicMDT
Abbott logo
AbbottABT
Cognizant logo
CognizantCTSH

Other financials

Income statement

See full
Revenue$247.2M+5.5%
Gross profit$136.8M+15.5%
Operating income-$17.4M+85.6%
Net income-$20.4M+84.4%
EPS (diluted)-$0.30+84.8%

Balance sheet

See full
Cash & equivalents$179.3M+235%
Total debt$734.7M+49.0%
Total equity$132.4M-14.7%
Total assets$1.2B+25.1%

Cash flow

See full
Operating cash flow$11.1M+160%
CapEx$6.3M+111%
Free cash flow$4.8M+123%

Valuation

See full
Market cap$1.08B-19.8%
Enterprise value$1.64B-8.5%
P/S1.1×-0.3×

Profitability

See full
Gross margin54.9%+2.7pp
Operating margin-8.2%-2.9pp
Net margin-9.2%-3.1pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-65.7%-14.7pp
Debt / equity5.5×+2.4×
Current ratio3.6×+1.3×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tandem Diabetes Care's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Tandem Diabetes Care (TNDM) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $390.93M in Q1 2026.
How has Tandem Diabetes Care's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
Tandem Diabetes Care's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) increased by 24.1% year-over-year, from $315.05M to $390.93M.
What is the long-term trend for Tandem Diabetes Care's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Over 5 years (2020 to 2025), Tandem Diabetes Care's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a -12.3% compound annual growth rate (CAGR), from $390.32M to $202.03M.
What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.